A federal court in Massachusetts has granted Pfizer and BioNTech’s motion to put on hold Moderna’s lawsuit over alleged ...
News that the Biden administration is planning to push for Americans to get the updated COVID vaccines this fall caused several vaccine manufacturers' stock prices to rise Monday. Moderna CEO ...
Moderna Inc. announced Tuesday that its next-generation COVID vaccine produced better immune results in a late-stage trial than its previous vaccines, and will be a key part of its combination ...
Shares of Moderna ... vaccine data is interesting. In his words, says the data suggests the vaccine could potentially work in industries outside of melanoma. He has a buy rating, price target ...
Moderna pauses plans for Kenya vaccine plant amid declining COVID-19 vaccine demand in Africa. Losses from unfulfilled orders prompt strategic shift. Efforts to finalize deal with Kenyan government ...
Shares in drug developer Moderna shot up 14 per cent after the company said mid-stage trials for its COVID-19 vaccine were approved by the Food and Drug Administration on Thursday. Moderna ...
A Victorian coroner is investigating whether a young woman's death from heart inflammation after receiving her third Covid-19 jab was caused by the Moderna vaccine. Moderna's lawyers appeared ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. US biotech Moderna has put plans to build a vaccine plant in Kenya on hold, in a sign that moves to invest ...
It also had plans to start filling doses of its COVID vaccine in the continent as early as 2023. However, Moderna has not received any vaccine orders for Africa since 2022 amid waning demand ...
COVID-19 vaccine maker Moderna (NASDAQ:MRNA) announced Thursday that its plans to build a messenger RNA vaccine plant in Kenya are on hold as it weighs future demand for mRNA vaccines in Africa.
(Reuters) -Moderna said on Thursday it had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for COVID-19 vaccines. The move is in ...